Product Details

Verpanto-C Capsules combine a proton pump inhibitor with a prokinetic agent for the comprehensive management of gastroesophageal reflux and related motility disorders. Specifically, each capsule delivers Pantoprazole IP 40mg together with Cinitapride IP 1mg. As a result, it offers combined acid suppression and improved gastric motility in a single formulation.

The capsules combine:

• Pantoprazole IP (40mg) – A proton pump inhibitor that irreversibly blocks the H+/K+-ATPase enzyme in gastric parietal cells. Consequently, it suppresses gastric acid secretion, relieving symptoms of acid reflux and supporting healing of the oesophageal lining.
• Cinitapride IP (1mg) – A prokinetic agent that acts on serotonergic receptors to enhance gastric and intestinal motility. As a result, it complements acid suppression by addressing the underlying motility component of reflux, bloating, and early satiety.

Physicians prescribe Verpanto-C for the management of gastroesophageal reflux disease (GERD) accompanied by symptoms of delayed gastric emptying, bloating, or functional dyspepsia. In addition, its combined mechanism addresses both acid-related and motility-related components of upper gastrointestinal symptoms. Because of this profile, Verpanto-C suits gastroenterology and general practice settings managing complex reflux and dyspeptic conditions.

Key Features:

• Overall, this combination formulation guarantees pharmaceutical-grade purity across both actives
• Additionally, the dual-mechanism formula addresses both acid suppression and gastric motility
• Furthermore, each capsule delivers precise, validated dosage accuracy at 40mg + 1mg
• Notably, rigorous quality testing backs every stage of manufacturing
• Beyond that, blister packaging protects capsule integrity against direct sunlight
• Ultimately, a reliable supply chain suits bulk distribution to hospitals, clinics, and pharmacies